CORE Biomedicine
Developing the next generation of precision medicines by going beyond genomics.
$21MSeries A
Role not disclosedMU
Mitsubishi UFJ Capital Co
Activity from announced rounds
Activity in this selectionhlm-investment-partners-579dd709
- Rounds participated in
- 2
- Confirmed lead rounds
- — 2 roles undisclosed
- New companies
- 2 First participation on record · 0 follow-on
- Funding in participating rounds
- $31.6M 2 disclosed · full round size, not this investor’s share
By stage
By primary sector
By country
Rounds
2 in this selectionRege Nephro Co
Developing innovative therapies and medical technologies for patients with kidney diseases who currently have limited treatment options
$10.6MSeries C
Role not disclosed